All In Biotech

Drug Trial Radar · NCT07920159

Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian Cancer

A Prospective, Single-Arm, Single-Center Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian Cancer Stratified by the CA-125 ELIMination Rate Constant K (KELIM)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

76

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Sep 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Anhui Provincial HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with advanced high-grade serous ovarian cancer who underwent primary cytoreductive surgery and received adjuvant chemotherapy with paclitaxel plus carboplatin were included. CA125 levels were dynamically monitored within 100 days post-surgery, and the KELIM value was calculated to identify patients at high risk of recurrence with a KELIM \< 1.

Conditions

  • High-grade Serous Ovarian Cancer

Interventions

  • SuvemcitugDrug

    The enrolled patients received sutilitaxel 2 mg/kg, administered once every 3 weeks, in combination with the Paclitaxel combined with Carboplatin regimen for intensified treatment from Cycle 4 to Cycle 6, and then received sutilitaxel monotherapy for maintenance treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From the date of definitive surgery to the first documented disease recurrence or death from any cause, whichever occurs first, assessed up to 36 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.